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ZUSAMMENFASSUNG 
Hintergrund:  Bei der Leberzirrhose trägt ein erhöhter intrahepatischer 
Gefäss-Widerstand zur portalen Hypertension bei. Der RhoA/Rho-Kinase Signalweg ist 
einer der Hauptmechanismen, der zur Kontraktion glatter Gefässmuskulatur führt. Wir 
untersuchten, ob dieser Signalweg eine Rolle für den erhöhten intrahepatischen 
Durchblutungswiderstand bei Ratten mit sekundär biliärer Leberzirrhose spielt.  
Methodik: Bei Ratten mit sekundär biliärer Leberzirrhose durch Gallengangsligatur 
(bile-duct ligation, BDL) und sham-operierten Kontrolltieren wurde über quantitative 
RT-PCR und Western-Blot Analyse die hepatische RhoA- und Rho-Kinase-Expression 
untersucht. Die Rho-Kinase Aktivität wurde als Phosphorylierung ihres Substrates, Moesin, 
bestimmt (Western-Blot Analyse, Immunohistochemie). In in situ perfundierten Lebern 
wurde der Effekt des Rho-Kinase Inhibitors Y-27632 auf den basalen und 
Methoxamin-stimulierten (alpha1-Adrenozeptor Agonist) Perfusionswiderstand untersucht. 
In anästhesierten Ratten wurde der hämodynamische Effekt einer intravenösen 
Applikation von Y-27632 untersucht (invasive Druckmessungen, kolorierte Mikrosphären).  
Ergebnisse: Sowohl die mRNA- als auch die Protein-Expression von RhoA und 
Rho-Kinase waren in Lebern von BDL Ratten im Vergleich zu Lebern sham-operierter 
Kontrolltiere erhöht. Die Moesin-Phosphorylierung (Thr-558) war in Lebern zirrhotischer 
Ratten und auch von Patienten mit Alkohol-induzierter Leberzirrhose im Vergleich zu den 
zugehörigen nicht-zirrhotischen Kontrollen erhöht. Der Perfusionsdruck in situ 
perfundierter Lebern war bei BDL Ratten erhöht, und wurde bei BDL Ratten, nicht aber 
sham-operierten Ratten, durch Y-27632 gesenkt. Der Effekt von Y-27632 auf die 
Methoxamin-Hypersensitivität in situ perfundierter Lebern von BDL Ratten war stärker 
ausgeprägt als der Effekt auf die intrahepatische Methoxamin-Sensitivität sham-operierter 
Ratten. In vivo führte Y-27632 bei BDL Ratten, nicht aber bei sham-operierten Ratten, über 
eine Verminderung des intrahepatischen Widerstandes zu einer Senkung des 
Pfortaderdruckes.  
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Diskussion: Eine erhöhte Expression und nachfolgende Überaktivierung des 
RhoA/Rho-Kinase Signalweges trägt bei BDL Ratten zur Erhöhung des intrahepatischen 
Widerstandes, und so zur portalen Hypertension bei. 
Keywords: cirrhosis; portal hypertension; intrahepatic vascular resistance; RhoA; 
Rho-kinase  
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INTRODUCTION   
Increased resistance to portal blood flow is a primary factor in the pathophysiology of portal 
hypertension [1–4]. Anatomical abnormalities—such as narrowing of intrahepatic 
microvessels because of fibrosis—are a major cause of the increased resistance to portal 
flow. However, a dynamic component caused by an abnormally active contraction of the 
hepatic microvasculature plays an additional role in the development of increased 
intrahepatic resistance [5, 6]. This part of the intrahepatic resistance to portal flow is 
regulated by intrahepatic portal venules and hepatic stellate cells (HSCs) [7, 8]. Decreased 
formation and action of the vasodilator nitric oxide in the hepatic vascular bed supports the 
presence of portal hypertension [5, 9-16]. Furthermore, the intrahepatic resistance of 
cirrhotic livers shows hyperresponsiveness to vasoconstrictors such as noradrenaline 
(norepinephrine) and endothelin [5, 6, 17-22]. 
The RhoA/Rho-kinase pathway is essentially involved in vasoconstriction and the 
regulation of vascular tone [23-30]. The pathway is activated by contractile agonists 
through G-protein coupled vasopressor receptors (fig 1). These receptors activate the small 
monomeric GTPase, RhoA. Thereafter, RhoA activates Rho-kinase, which subsequently 
inhibits myosin-light-chain-phosphatase (MLC-phosphatase). Inhibition of 
MLC-phosphatase results in enhanced phosphorylation of MLCs and contraction. 
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Figure 1 RhoA/Rho-kinase mediated vasoconstriction. The RhoA/Rho-kinase pathway is essentially involved in 
contraction of vascular smooth muscle and is linked to G-protein coupled receptors for vasoconstrictors. The 
initial event is the activation of the small monomeric GTPase RhoA by receptor associated heterotrimeric 
G-proteins containing α subunits of the Gαq/11 and Gα12/13 family. RhoA activation is associated with an 
exchange of GDP to GDP at the protein. GTP-RhoA subsequently activates Rho-kinase. Rho-kinase in turn 
phosphorylates and inhibits myosin-light-chain phosphatase. Inhibition of myosin-light-chain phosphatase 
results in enhanced phosphorylation of myosin-light-chains, which is the ultimate prerequisite for contraction of 
vascular smooth muscle. GDP, guanosine diphosphate; GTP, guanosine triphosphate. 
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Although it has been reported that RhoA is expressed in activated HSCs and that the 
RhoA/Rho-kinase pathway plays an important role in HSC activation and hepatic 
fibrogenesis [31-41], the actions of this pathway in the regulation of intrahepatic resistance 
to portal blood flow remain unknown. We therefore studied the role of the RhoA/Rho-kinase 
pathway in the intrahepatic vascular resistance of rats with secondary biliary cirrhosis and 
investigated whether it is involved in the pathogenesis of portal hypertension. 
 
METHODS 
Animals 
Male Sprague-Dawley rats (180 to 200 g) were obtained from Charles River Laboratories 
(Sulzfeld, Germany) and maintained on standard chow on a 12 hour light/dark cycle. The 
rats were randomly divided into two groups. In one group, bile duct ligation was carried out 
as previously described [42]. Briefly, rats were anaesthetized with ketamine hydrochloride 
(100 mg/kg); the common bile duct was exposed by an upper abdominal midline incision of 
1.5 cm and was ligated twice with 5-0 silk suture and resected between the ligatures; 
muscle and skin were sutured separately with 3-0 silk. The rats of the other group were 
sham operated and served as controls. These animals therefore experienced the same 
procedures except that the bile duct was manipulated but not ligated and sectioned. 
The study was approved by the local committee for animal studies (administrative authority, 
Cologne, Germany, 50.203-Bn 15, 23/03).  
Patients
Samples of liver tissue from patients with alcohol induced cirrhosis (n = 3) were obtained 
during liver transplantation. Non-tumour-bearing liver tissue obtained during resection of 
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liver malignancies served as normal control (n = 3). The use of human liver specimens was 
approved by the local ethics committee.  
Western blot analysis
Samples of shock frozen livers were homogenized in a buffer containing 25 mM Tris/HCl, 5 
mM ethylenediamine tetra-acetic acid, 10 μM phenylmethanesulphonyl fluoride, 1 mM 
benzamidine, and 10 μg/ml leupeptin. Protein determination of the homogenates was 
carried out with the Dc-Assay kit (Biorad, Munich, Germany). Thereafter, homogenates 
were diluted with sample buffer. Samples (20 μg of protein per lane) were subjected to 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (15% gels for 
RhoA, 8% gels for Rho-kinase), and proteins were blotted on nitrocellulose membranes. 
The membranes were blocked, incubated with primary antibodies (RhoA 119 and Rock-2 
H-85, Santa Cruz Biotechnology, Santa Cruz, California, USA) and thereafter with 
corresponding secondary peroxidase coupled antibodies (Calbiochem, San Diego, 
California, USA). Blots were developed with enhanced chemiluminescence (ECL, 
Amersham, UK). Intensities of the resulting bands on each blot were compared 
densitometrically with a FLA-3000 phosphoimager (Fuji-Film, Düsseldorf, Germany).  
Quantitative real time reverse transcription polymerase chain 
reaction
RNA was isolated from 30 mg shock frozen liver tissue using the RNeasy-mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s guidelines. RNA concentrations were 
measured spectrophotometrically at 260 nm. For each sample, 1 μg of total RNA was used. 
Before reverse transcription, samples were DNA digested with RQ1 RNase-free DNase 
(Promega, Madison, Wisconsin, USA). Reverse transcription was carried out using 
Moloney murine leukaemia virus (MMLV) reverse transcriptase (Invitrogen, Karlsruhe, 
Germany) and random primers (250 ng, Microsynth, Balgach, Switzerland). Control 
reactions did not contain reverse transcriptase. Primers and probes for real time reverse 
transcription polymerase chain reaction (RT-PCR) were designed using the Primer 
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Express Software (Applied Biosystems, Foster City, California, USA) and custom 
synthesised by Microsynth and Applied Biosystems, respectively. Sequences of the 
primers and probes are given in table 1. Primers and probes for the housekeeping gene 
(18SrRNA) were provided by Applied Biosystems as a ready-to-use mix. RT-PCR was 
carried out using the ABI 7700 sequence detector (Applied Biosystems). The PCR reaction 
was done in a volume of 25 μl containing 12.5 μl 2x TaqMan PCR master mix (Roche 
Molecular Systems, Mannheim, Germany/Applied Biosystems) and 2 μl cDNA (equivalent 
to 67 ng total RNA). The final concentrations of the primers and probes are given in table 1. 
18SrRNA served as the endogenous control. The final concentrations were 100 nM for 
primers and 200 nM for the probe. The results are expressed as the number of cycles (CT 
value) at which the fluorescence signal exceeded a defined threshold. The difference in CT 
value of the target cDNA and the endogenous control are expressed as negative ΔCT 
values (–ΔCT). Thus higher –ΔCT values denote higher mRNA levels. The ΔCT method was 
used for quantification of the results. For all target genes and 18SrRNA, validation 
experiments were carried out according to the manufacturer’s guidelines. In these 
experiments, it was shown that the efficiencies of the RT-PCR for the target gene and the 
endogenous control were approximately equal. Thus the ΔCT method is suitable for relative 
quantification.  
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Gene Primer/probe sequence 5'-3' (forward/reverse/probe) Primer/probe concentration (nM) 
RhoA GGCAGAGATATGGCAAACAGG, 300 
 TCCGTCTTTGGTCTTTGCTGA, 300 
 CACTCCATGTACCCAAAAGCGCCAAM 100 
Rho-kinase CCCGATCATCCCCTAGAACC, 300 
 TTGGAGCAAGCTGTCGACTG, 300 
 ACAAAACCAGTCCATTCGGCGGC 200 
 
Table 1  Primers and probes used for quantitative reverse transcription polymerase chain reaction for RhoA 
and Rho-kinase
Assessment of Rho-kinase activity 
Rho-kinase activity was assessed as phosphorylation of the endogenous Rho-kinase 
substrate, moesin, at thr-558 [43-48]. This was done by western blot analysis using a site 
specific and phosphospecific anti-moesin antibody (Santa Cruz Biotechnology). In parallel, 
total moesin was analysed using a non-phosphospecific antibody (Santa Cruz 
Biotechnology).  
Immunohistochemistry 
Immunohistochemical staining of liver sections was carried out using the indirect 
immunoperoxidase technique as previously described [49] with the exception that the 
incubation with the primary antibody (site specific and phosphospecific anti-moesin 
antibody) was prolonged (overnight), and a swine anti-rabbit antibody (Dako, Carpinteria, 
California, USA) was used as secondary antibody.  
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In situ liver perfusion 
In situ liver perfusion was carried out in a recirculating system according to a previously 
described technique [9]. Briefly, rats were fasted overnight but allowed free access to water. 
Only cirrhotic rats with ascites were included in the study. After being anaesthetised with 
ketamine hydrochloride (60 mg/kg), the abdomen was opened and the bile duct was 
cannulated with a polyethyl tube to monitor bile flow. Loose ligatures were placed around 
portal vein, common hepatic artery, spleen vein, and posterior vena cava just cranially to 
the confluence of the right renal vein. A 500 U dose of heparin was injected into the 
posterior vena cava. The portal vein was cannulated with a 14-gauge Teflon catheter, 
initiating liver exsanguinations by infusion (30 ml/min) of Krebs-Henseleit solution 
containing heparin (2 U/ml) and oxygenated with carbogen (95% O2, 5% CO2). The 
posterior vena cava was immediately cut caudally to the loose ligature, allowing the 
perfusate to escape. Thereafter, the thorax was opened and the right atrium was cut. 
Another catheter was introduced in the right atrium and pushed forward to the inferior vena 
cava. Next, all ligatures were pulled tight. At a constant flow (30 ml/min), perfusion 
pressure was monitored continuously and recorded digitally on-line. The preparation was 
allowed to stabilize for 20 minutes without any procedure.  
Viability and stability of liver perfusion preparation 
The criteria for liver viability included gross appearance of the liver, stable perfusion, bile 
production >0.4 μl/min*g, and stable buffer pH (7.4±0.1) during the initial 20 minute 
stabilization period. If one of the viability criteria was not met, the experiment was 
discarded.  
Effect of the α1 adrenoceptor agonist methoxamine on portal 
perfusion pressure 
In one set of experiments, livers were initially perfused at a constant flow (30 ml/min) for a 
period of 20 minutes without any procedure in order to stabilize the entire system. Then 
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cumulative concentration–response curves with the α1 adrenoceptor agonist methoxamine 
(0.1 μM to 100 μM) were obtained by addition of the agonist to the perfusate. Changes in 
perfusion pressure were expressed either as the absolute perfusion pressure after 
administration of methoxamine, or as change in perfusion pressure elicited by the given 
concentration of methoxamine in the perfusate (that is, perfusion pressure minus basal 
pressure).  
Effect of the Rho-kinase inhibitor Y-27632 on methoxamine 
induced hepatic flow resistance 
In another set of experiments, 10 minutes before addition of the first dose of methoxamine, 
Y-27632 was added to the perfusate in different concentrations (1, 10, and 30 μM). 
Thereafter, cumulative concentration–response curves for methoxamine were constructed 
as described above.  
Haemodynamic studies 
Haemodynamic studies were carried out under ketamine anaesthesia (60 mg/kg 
intravenously). This condition has been shown to approximate most closely the conscious 
state in terms of cardiac output and regional blood flow and has been used extensively to 
investigate the haemodynamic effects of portal pressure lowering drugs in animal models of 
portal hypertension [2, 42, 50, 51]. The left femoral artery and vein were cannulated with 
PE-50 catheters for measurement of arterial pressure and blood withdrawal, as well as for 
drug infusion. Median laparotomy was carried out and a PE-50 catheter was introduced into 
a small ileocaecal vein and advanced to the confluence of the portal and splenic vein for 
the measurement of portal pressure. Through the right carotid artery another PE-50 
catheter was advanced into the left ventricle under pulse curve control. This catheter was 
used for microsphere application. The catheters in the femoral artery and the portal vein 
were connected to pressure transducers (Hugo Sachs Electronic, March-Hugstetten, 
Germany) for blood pressure measurement. The zero point was 1 cm above the operating 
table. 
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Regional blood flows were measured using the coloured microsphere method, as 
previously described [42, 52]. A reference sample was obtained for one minute at a rate of 
0.65 ml/min using a continuous withdrawal pump (Hugo Sachs Electronic). Then 300 000 
yellow microspheres (15 μm diameter, Triton Technologies, San Diego, USA) were 
suspended in 0.3 ml saline containing 0.05% Tween and injected into the left ventricle 10 
seconds after the withdrawal pump had been started. Upon completion of the 
haemodynamic measurements the animals were killed and the lungs, liver, kidneys, 
stomach, intestine, pancreas, and spleen were resected. The tissues were weighed, 
minced with scissors, and digested by addition of 14 ml/g tissue of 4 M KOH with 2% 
Tween, and subsequent boiling for one hour. The blood reference sample was digested by 
the addition of 3.8 ml 5.3 M KOH and 0.5 ml Tween and subsequent boiling for one hour. 
The digested tissues and blood samples were vortexed and filtered using Whatman 
Nucleopore filters (Whatman International, Maidstone, UK). The colour of the filtered 
microspheres was dissolved in 0.2 ml N,N-dimethylformamide and the absorption was 
measured by spectrophotometry. Thereafter, the number of microspheres per organ and 
organ perfusion was calculated using software obtained from Triton Technologies. 
Porto-systemic shunting (PSS) was estimated as previously described, after the injection of 
150 000 blue microspheres in 0.3 ml saline containing 0.05% Tween into an ileocaecal vein 
within 30 seconds [42,53]. The tissue microsphere content was calculated as described for 
the measurement of organ blood flow. PSS was calculated as the number of microspheres 
in the lungx100 divided by the number of microspheres in lung and liver. Portal venous 
inflow (PVI) was calculated as the sum of the blood flows to stomach, spleen, intestines, 
pancreas, and mesentery. Collateral blood flow (ml/minx100 g) was estimated as 
PVIxPSS/100. Vascular resistances were calculated from the ratio between perfusion 
pressure and blood flow of each vascular territory.  
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Statistical analysis 
Data are presented as means (SEM) with the indicated number (n) of experiments. 
Analysis of variance (ANOVA) followed by Bonferroni/Dunn or the Mann–Whitney U test 
was used for comparison between groups (StatView 5.0, SAS Institute, Cary, North 
Carolina, USA). Probability (p) values of <0.05 were considered statistically significant. For 
the analysis of the in situ liver perfusion studies with methoxamine, 
concentration–response curves were fitted by non-linear regression, using the computer 
program Prism® (Graph Pad Software Inc, San Diego, California, USA). Emax (maximum 
contraction) and pEC50 values (negative logarithm of the concentration producing a half 
maximum effect) were calculated from the fitted curves.  
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RESULTS 
Hepatic expression of RhoA and Rho-kinase 
Western blot analysis of whole liver homogenates showed a strong upregulation of RhoA 
and Rho-kinase protein levels in livers from BDL rats compared with sham operated rats 
(fig 2A). In parallel, as revealed by quantitative RT-PCR with mRNA isolated from whole 
liver homogenates, both RhoA and Rho-kinase mRNA were significantly raised in livers 
from sham operated and BDL rats (fig 2B). 
 
Figure 2 Hepatic RhoA and Rho-kinase expression in sham operated and bile duct ligated (BDL) rats. (A) 
Protein expression, western blot analysis. Shown are representative western blots of whole liver homogenates 
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and densitometric quantification of all experiments. Data are means with SEM, n = 8–10 for each group. (B) 
mRNA expression, data from quantitative reverse transcription polymerase chain reaction. Shown are mRNA 
levels in whole liver homogenates from both groups (sham n = 7, BDL n = 6). d.u., densitometric units.  
Hepatic moesin phosphorylation 
Phosphorylation of moesin—a marker for Rho-kinase activity [43-48] was greatly increased 
in livers of BDL rats (fig 3A). This difference was not associated with changes in total 
moesin, which was similar in both groups (fig 3A). As thr-558 of moesin is preferentially 
phosphorylated by Rho-kinase, these findings probably reflect an increased basal 
Rho-kinase activity in livers of BDL rats. 
To localize the sites of intrahepatic moesin hyperphosphorylation in BDL rats, 
immunohistochemical investigations for phospho-moesin were undertaken in liver sections 
from sham operated and BDL rats. Phosphorylated moesin was highly present within the 
walls of the intrahepatic branches of portal venules and hepatic arteries (fig 4). The staining 
for phospho-moesin within these vessel walls was significantly stronger in BDL rats than in 
sham operated rats, and to some degree in the hepatic arteries (fig 4). In contrast, no 
phospho-moesin was detected in the remaining intrahepatic sites (hepatocytes or 
extracellular space), and only weak staining in the perisinusoidal cells (fig 4). 
The phosphorylation state of moesin was also investigated by western blot analysis in 
human livers (whole liver homogenates from cirrhotic v non-cirrhotic patients). These 
experiments showed a clear trend towards raised phospho-moesin levels in livers from 
cirrhotic patients (alcohol induced cirrhosis) when compared with those from non-cirrhotic 
patients (fig 3B). 
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Figure 3 Total and phospho-moesin in whole liver homogenates in rat (A) and human (B) cirrhosis. Moesin is 
phosphorylated at threonine 558 by Rho-kinase. (A) Phospho-moesin and total moesin in livers from sham 
operated and bile duct ligated (BDL) rats (n = 5–6 for each group). (B) Phospho-moesin in livers from cirrhotic 
and non-cirrhotic patients (n = 3/group). Representative western blots of whole liver homogenates and 
densitometric quantification of all experiments are shown. Data are means with SEM; d.u., densitometric units. 
 
19 
 
Figure 4 Immunohistochemical staining of liver sections from sham operated (n = 7) and bile duct ligated (BDL) 
rats (n = 7) for phospho-moesin. Representative experiments are shown, with quantification of the staining in the 
intrahepatic branches of the portal venules (P.v.) and hepatic arteries (H.a.). Data are means with SEM, n = 7 for 
each group (quantification was carried out in triplicate for each animal).  
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Basal intrahepatic resistance and modulation by Rho-kinase 
inhibition 
At a constant flow, changes in perfusion pressure reflect changes in intrahepatic resistance. 
In BDL rats, the perfusion pressure of in situ perfused livers was on average increased 
threefold (fig 5A). In order to assess whether increased hepatic expression and activity of 
Rho-kinase is related to intrahepatic vascular resistance, we tested the effect of the 
Rho-kinase inhibitor Y-27632 on perfusion pressure. Y-27632 had no significant effects at 
any concentration on perfusion pressure in sham operated rats (fig 5B). In contrast, in BDL 
rats intrahepatic perfusion pressure was significantly reduced by 10 μM and 30 μM of 
Y-27632 (fig 5B). 
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Figure 5.  Basal perfusion pressure of in situ perfused livers (A), and effect of Rho-kinase inhibition with 
Y-27632 on basal perfusion pressure (B). Data are means with SEM, n = 9–10 in each group. BDL, bile duct 
ligated; sham, sham operated. 
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Effect of Rho-kinase inhibition on methoxamine induced 
increase in intrahepatic resistance 
To investigate the role of the RhoA/Rho-kinase pathway in vasoconstrictor mediated 
regulation of intrahepatic microvascular tone, we studied the effect of Y-27632 on the 
methoxamine induced increase in intrahepatic perfusion pressure. As shown in fig 6A, the 
addition of methoxamine to the perfusate elicited dose dependent increases in perfusion 
pressure in both groups. The sensitivity of livers from BDL rats to methoxamine was 
significantly greater than in sham operated rats, as shown by the increase in EC50 (fig 6C, 
left columns). This underlines the well known hyperreactivity of the hepatic vascular 
resistance of cirrhotic livers to vasoconstrictors. However, the changes in perfusion 
pressure (Pmax) elicited by the maximum concentration of methoxamine (100 μM) were 
similar in both groups (fig 6, A and D, left panels), although the perfusion pressures 
reached in BDL rats were higher than in sham operated rats, owing to the higher basal 
intrahepatic perfusion pressure.  
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Figure 6 (A) Concentration–response curves for the effect of the α1 adrenoceptor agonist methoxamine on the 
perfusion pressure of in situ perfused livers from sham operated (sham) and bile duct ligated (BDL) rats. (B) 
Effect of Rho-kinase inhibition with Y-27632 on the dose dependent methoxamine induced increase in perfusion 
pressure of in situ perfused livers. (C) Effect of Rho-kinase inhibition with Y-27632 on the methoxamine 
sensitivity of in situ perfused livers from sham operated and BDL rats. * p<0.002 v sham without Y-27632; † 
p<0.0004 v sham without Y-27632; ‡ p<0.0006 v sham without Y-27632; ¶ p<0.003 v BDL without Y-27632. (D) 
Reduction of methoxamine (100 μM) induced increase in perfusion pressure by Rho-kinase inhibition with 
Y-27632 in livers from sham operated and BDL rats perfused in situ. Data are means with SEM, n = 9–10 in 
each group. * p<0.0001 v sham without Y-27632; † p<0.0005 v BDL without Y-27632. p[methoxamine], negative 
decadic logarithm of a given concentration of methoxamine. 
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Next, we tested the effect of different concentrations of Y-27632 on the dose dependent 
methoxamine induced increase in intrahepatic resistance. The addition of 1 μM Y-27632 
had no effect on the methoxamine induced increase in intrahepatic perfusion pressure in 
sham operated and BDL rats (fig 6, panels B and D). However, in sham operated rats, 10 
μM and 30 μM Y-27632 significantly inhibited the Pmax induced by 100 μM methoxamine (fig 
6, panels A and D). In contrast, in BDL rats, only 30 μM Y-27632 significantly inhibited the 
methoxamine (100 μM) stimulated increase in perfusion pressure (fig 6D). Y-27632 10 μM 
and 30 μM significantly increased the EC50 to methoxamine of perfused livers from sham 
operated rats (fig 6C). By contrast, in BDL rats, only the 30 μM concentration of Y-27632 
was able to affect the EC50 to methoxamine (fig 6C).  
Haemodynamic in vivo effects of Rho-kinase inhibition 
To obtain further insight into the regulation of portal pressure through the RhoA/Rho-kinase 
pathway in vivo, we studied the haemodynamic effects of bolus injection of different doses 
of Y-27632. 
As expected, BDL rats had increased portal pressure, low arterial pressure, decreased 
splanchnic vascular resistance, increased intrahepatic resistance, and increased 
porto-systemic shunt flow. Bolus injection of Y-27632 (0.1 mg/kg) reduced portal pressure 
in BDL but not in sham operated rats (fig 7A). Interestingly, this was paralleled by a 
significant decrease in hepatic vascular resistance in BDL rats but not in sham operated 
rats (fig 8A). In contrast, splanchnic vascular resistance and hepatic arterial flow were 
unaffected in BDL rats, but reduced in sham operated rats after bolus injection of 0.1 mg/kg 
Y-27632 (fig 7, panels C and D). The shunt volume in BDL rats was significantly increased 
after Y-27632 (fig 8B). In both groups, the systemic administration of 0.1 mg/kg Y-27632 
did not change mean arterial pressure (fig 7B). Bolus injection of Y-27632 in a dose of 1 
mg/kg elicited large and sustained decreases in portal pressure in BDL rats but had no 
effect on portal pressure in sham operated rats (fig 7A). The reduction in portal pressure in 
response to the high dose of Y-27632 was associated with a further reduction in hepatic 
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vascular resistance (but also with further increases in portal venous inflow and shunt 
volume) in BDL rats, but not in sham operated rats (fig 8). In both groups, 1 mg/kg of 
Y-27632 induced large sustained decreases in mean arterial pressure (fig 7B), significant 
decreases in splanchnic vascular resistance, and significant increases in hepatic arterial 
flow (fig 7, panels C and D). 
 
Figure 7 (A) Dose dependent in vivo effects of intravenous application of the Rho-kinase inhibitor Y-27632 on 
portal pressure in sham operated (sham) and bile duct ligated (BDL) rats, determined 45 minutes after bolus 
injection. (B) Dose dependent in vivo effects of intravenous application of the Rho-kinase inhibitor Y-27632 (0.1 
and 1 mg/kg bw) on mean arterial pressure in sham operated and BDL rats, determined 45 minutes after bolus 
injection. Data are means with SEM, n = 11–27 in each group. (C) Dose dependent in vivo effects of intravenous 
application of the Rho-kinase inhibitor Y-27632 (0.1 and 1 mg/kg bw) on splanchnic vascular resistance in sham 
operated and BDL rats, determined 45 minutes after bolus injection. (D) Dose dependent in vivo effects of 
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intravenous application of the Rho-kinase inhibitor Y-27632 (0.1 and 1 mg/kg bw) on hepatic arterial flow in 
sham operated and BDL rats, determined 45 minutes after bolus injection. Data are means with SEM, n = 11–27 
in each group. bw, body weight. 
 
Figure 8  Dose dependent in vivo effects of intravenous application of the Rho-kinase inhibitor Y-27632 
(0.1 and 1 mg/kg bw) on hepatic vascular resistance (A), shunt volume (B), and portal venous flow (C) in sham 
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operated (sham) and bile duct ligated (BDL) rats, determined 45 minutes after bolus injection. Data are means 
with SEM, n = 11–16 in each group. 
DISCUSSION 
The results of the present study provide evidence for the contribution of an abnormal 
increase in intrahepatic Rho-kinase signalling to the increased intrahepatic resistance and 
the increased sensitivity of the hepatic resistance to vasoconstrictors observed in rats with 
secondary biliary cirrhosis. An increased resistance of the intrahepatic microcirculation to 
portal flow contributes essentially to portal hypertension. Thus the intrahepatic regulation of 
liver blood flow by abnormal vasoconstrictor and vasodilator mediated signalling in 
cirrhosis has been studied widely [5.6.9-22]. To date, two mechanisms have been revealed 
which contribute functionally to the increased vascular tone in the cirrhotic liver. Increased 
intrahepatic resistance in cirrhosis is mediated by a decreased formation and action of the 
vasodilator nitric oxide (NO), and an increased sensitivity to vasoconstrictors (for example, 
α1 adrenoceptor agonists and endothelin) [5.6.9-22]. This increased sensitivity to 
vasoconstrictors is not completely understood. Vasoconstrictor mediated signalling 
downstream of the level of G protein coupled vasopressor receptors could play a role. 
Therefore, we investigated the RhoA/Rho-kinase pathway in the vasoconstrictor mediated 
intrahepatic regulation of liver blood flow. It has been shown that this pathway is essentially 
involved in contraction of vascular smooth muscle [23-30]. Furthermore, a role for 
RhoA/Rho-kinase mediated signalling in activation and contraction of hepatic stellate cells 
as well as in hepatic fibrogenesis has also been demonstrated [31-41]. 
First, we investigated expression of RhoA and Rho-kinase in livers from sham operated 
and BDL rats. There was a strong upregulation of RhoA and Rho-kinase protein expression 
as well as mRNA expression in livers of rats with secondary biliary cirrhosis. The functional 
activity of Rho-kinase can be assessed as the phosphorylation state of its substrate moesin 
[43-48]. The hepatic upregulation of RhoA and Rho-kinase in cirrhotic rats indeed resulted 
in an increased moesin phosphorylation, reflecting an increased activity of Rho-kinase in 
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these animals. Most of the phosphorylated moesin found by immunohistochemical staining 
was localised to the walls of intrahepatic branches of portal venules and hepatic arteries, 
and to a lesser extent in perisinusoidal cells. Moesin phosphorylation in presinusoidal 
portal venules was highly increased in BDL rats. A similar increase in moesin 
phosphorylation was found by western blot analysis in liver homogenates from patients with 
alcohol induced cirrhosis. This indicates that these processes are not restricted to the 
animal model used here, but may probably be of clinical relevance. 
To assess the functional relevance of the increased hepatic expression of RhoA and 
Rho-kinase and the subsequent increase in Rho-kinase activity for the hepatic vascular 
resistance of BDL rats, we tested the effect of the Rho-kinase inhibitor Y-27632 on the 
basal perfusion pressure of in situ perfused livers. Basal perfusion pressure at a constant 
flow (that is, the intrahepatic resistance to portal flow) was increased in BDL rats. Inhibition 
of Rho-kinase by Y-27632 reduced the basal perfusion pressure in BDL rats but not in 
sham operated rats. Thus the intrahepatic microcirculation in BDL rats was more 
susceptible to Rho-kinase inhibition than that of sham operated rats. As these findings were 
obtained under conditions excluding the influence of circulating vasoactive mediators, they 
possibly reflect an increased contribution of Rho-kinase to the increased basal vascular 
tone of the intrahepatic microvasculature in BDL rats. 
Next, we studied the dose dependent changes in perfusion pressure after stimulation with 
the α1 adrenoceptor agonist methoxamine in both groups. Livers from BDL rats were 
hypersensitive to methoxamine, as shown by the decreased EC50. This increased 
sensitivity of livers from BDL rats to methoxamine shows the exaggerated response of 
cirrhotic livers to vasoconstrictors. To study the role of the RhoA/Rho-kinase pathway in the 
regulation of vasoconstrictor induced intrahepatic vascular tone, we examined the effect of 
different doses of Y-27632 on the methoxamine stimulated changes in perfusion pressure. 
In sham operated rats, Rho-kinase inhibition with Y-27632 at a concentration of 10 μM was 
already able to decrease the pEC50 for methoxamine. In contrast, at least 30 μM of 
Y-27632 was necessary to elicit the same effect in BDL rats. Furthermore, contractions 
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elicited by methoxamine were less susceptible to Rho-kinase inhibition in BDL rats than in 
sham operated rats. 
These data permit several conclusions. First, contractile G-protein coupled receptors (for 
example, α1 adrenoceptors) in the intrahepatic microvasculature are coupled to the 
RhoA/Rho-kinase pathway. Thus the RhoA/Rho-kinase pathway is indeed involved in the 
adrenergic regulation of intrahepatic vascular tone. Second, in BDL rats compared with 
sham operated rats, activation of the RhoA/Rho-kinase pathway in response to α1 
adrenergic stimulation of intrahepatic microcirculation is probably increased. 
To investigate the role of the Rho-kinase signalling in intrahepatic resistance to liver blood 
flow and portal pressure in vivo, we studied the effects of systemic administration of the 
Rho-kinase inhibitor Y-27632 in anaesthetised rats. Portal pressure was dose dependently 
reduced in response to bolus injection of Y-27632 in cirrhotic but not in non-cirrhotic rats. 
Simultaneously, intrahepatic vascular resistance was decreased in BDL rats in response to 
Y-27632 but not in sham operated rats. 
Taken together, in BDL rats Y-27632 decreased portal vascular resistance and hepatic 
vascular resistance after intravenous application; furthermore, Y-27632 reduced the 
intrahepatic perfusion pressure in the in situ perfused cirrhotic liver. These effects were 
much less pronounced in the sham operated rat. Because Y-27632 also efficiently reduced 
the perfusion pressure of in situ perfused livers, we assume that the portal pressure 
lowering effect of Y-27632 observed in vivo is at least partially mediated by intrahepatic 
actions of the inhibitor. However, it cannot be excluded that Y-27632 also directly acts at 
the portal vein itself. The decrease in hepatic vascular resistance of BDL rats was 
accompanied by an increased porto-systemic shunting. As microspheres were injected into 
the portal vein through the superior mesenteric vein to study porto-systemic shunting, we 
assume that Y-27632 decreased intrahepatic resistance at least in part by opening 
intrahepatic shunts. Hepatic arterial flow was increased in BDL rats despite an increase in 
moesin phosphorylation in intrahepatic hepatic arteries, suggesting further regulatory 
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pathways in these vessels counterbalancing an increased Rho-kinase activity. A 
contribution of hepatic arteries to the regulation of intrahepatic resistance is unclear. By 
contrast, portal venules are a principal site of regulation of intrahepatic resistance and 
portal pressures. This is emphasised by the pronounced effect of Y-27632 in livers 
perfused in situ. 
The decrease in portal pressure was paralleled by a decrease in splanchnic vascular 
resistance. This decrease in splanchnic resistance might be explained by the vasodilating 
properties of Y-27632 on these vessels. Interestingly, the net decrease was greater in 
sham operated rats than in BDL rats, suggesting a reduced Rho-kinase activity in the 
splanchnic vasculature of the cirrhotic rats, which might contribute to the abnormally 
persistent vasodilatation of these vessels. The decrease in splanchnic vascular resistance 
increased portal tributary flow. This should normally increase portal pressure. However, in 
our BDL rats, portal pressure was decreased despite an increase in portal tributary blood 
flow, suggesting that the Y-27632 induced decrease in intrahepatic vascular resistance 
overcomes the increase in portal tributary flow. Again, this highlights the role of the 
hyperactivation of the RhoA/Rho-kinase pathway in the hepatic vascular bed for portal 
hypertension of BDL rats. It remains to be shown whether similar abnormalities in 
Rho-kinase signalling also contribute to the increased hepatic vascular resistance in other 
models of cirrhosis of the liver. As an increase in moesin phosphorylation was also found in 
livers from patients with alcohol induced cirrhosis, it seems possible that the Rho-kinase 
mediated increase in hepatic vascular resistance is not restricted to biliary cirrhosis in rats, 
but is rather a common feature of cirrhosis of the liver. Arterial pressure and splanchnic 
vascular resistance were also reduced by Y-27632. However, at the lower dose, Y-27632 
reduced portal pressure in BDL rats without affecting arterial pressure. Thus most of the 
portal pressure lowering effect of Y-27632 seems to be mediated by decreasing 
intrahepatic resistance. Nevertheless, liver-specific drugs inhibiting the RhoA/Rho-kinase 
signaling preferentially in the cirrhotic liver should be developed before testing such drugs 
for pharmacological treatment of portal hypertension. Such Rho-kinase inhibiting drugs 
have the advantage that they also decrease hepatic fibrogenesis [38-41]. 
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In summary, increased intrahepatic resistance in rats with secondary biliary cirrhosis is 
associated with an upregulation of RhoA and Rho-kinase signalling. Inhibition of this 
pathway in the liver can reduce portal pressure in rats with secondary biliary cirrhosis. 
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